Event
Innovation Matchmaking - Oncology: Start-ups x Bavarian University Hospitals
25. September 2025
13:30 - 18:30
iStock©Franck-Boston + ©CaiaimageSam Edwards,
Innovation Matchmaking - Oncology: Start-Ups x Bavarian University Hospitals brings start-ups and clinicians together to jointly promote innovative solutions in oncology. The event promotes direct exchange between doctors and innovative start-ups in the field of oncology.
With the Innovation Matchmaking on the focus topic of oncology, together with our partner the Bavarian Center for Cancer Research (BZKF), we offer a platform that brings start-ups and clinicians together to highlight, discuss and jointly implement promising innovative solutions for everyday clinical practice.
Why should you participate as a clinician?
Gain insights into innovative solutions for everyday clinical practice from up-and-coming start-ups and exchange ideas with other clinicians on the implementation of innovations in everyday clinical practice. We also welcome clinicians from outside the BZKF network.
Why should you take part as a start-up?
Take advantage of the opportunity to get in touch with clinicians and potential users during the speed dating part and exchange ideas with other start-ups. Selected start-ups can pitch their solutions to the plenum. Are you a start-up with an innovation in the field of oncology and interested in a pitch? Then get in touch with us.
Your contact person
Merz-Fotografie,
Start-up pitches - Innovation in oncology
with the companies Piur Imaging GmbH, Just Health Gmbh, MyImmune, Inc., Immune Advice, Virtuhance, hema.to, ImuVeo
Robert Bauer,
RAYDIAX GmbH,
Florian Hauer,
Oliver Ullrich,
Hannes Schreiter,
Dominik Sonanini,
Moderation
Merz-Fotografie,
Robert Bauer,
Prof. Dr. Stefanie Corradini,
Matthias May,
Speed Dating - Start-up x Clinic
Participating groups of the BZKF at the Speed Dating:
- Lighthouse AI/Bioinformatics
- Lighthouse Cellular Immunotherapies
- Lighthouse Local Therapies
- Theranostics lighthouse
- AMBORA project
- Translational group: Determination of residual disease in AML using automated AI-supported analysis of flow cytometry data
- Data protection
Specialist contact person
Franziska Klein,
Organizational contact persons